Stryker to deal bone growth protein assets to Mariel Therapeutics

Stryker Corp. agrees to sell its bone morphogenetic protein-7 assets to Mariel Therapeutics, which plans to investigate BMP-7 as a possible treatment for a variety of conditions.

Mariel Therapeutics, Stryker Corp.

News Well, Mergers & Acquisitions, Pharmaceuticals, Resorbable bone materials

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1k56xRZ